Literature DB >> 7251131

Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen.

J J Vallotton, P C Frei.   

Abstract

It has been shown that (+)-cyanidanol-3, therapeutically administered during the course of acute hepatitis B, is able to favor the elimination of hepatitis B surface antigen (HBsAg) from the blood. This observation suggests that (+)-cyanidanol-3 might stimulate the cell-mediated immune response, since it is known that this type of response is responsible for elimination of the virus. In the present study, the possible action of (+)-cyanidanol-3 on this type of immunity was investigated by adding the substance in vitro to leukocyte migration inhibition tests, performed with the antigens purified protein derivative (PPD) and HBsAg and with leukocytes from individuals sensitized to these antigens. In normal individuals sensitized to PPD, the addition of (+)-cyanidanol-3 amplified the inhibition of migration by 7.0% (P less than 0.05). In patients previously infected by hepatitis B virus and sensitized to HBsAg, the addition of (+)-cyanidanol-3 amplified the migration inhibition by 10.5% (P less than 0.05). A trend to a dose-response relation was observed with the antigen PPD. (+)-Cyanidanol-3 did not modify leukocyte migration in the absence of an antigen. (+)-Cyanidanol-3 therefore seems capable of amplifying the cell-mediated immune response as measured by the leukocyte migration inhibition test. It is thus possible that it favors the elimination of HBsAg in patients by this mechanism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7251131      PMCID: PMC351461          DOI: 10.1128/iai.32.2.432-437.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Stabilization of rat liver lysosomes by (+)-cyanidanol-3 in vivo.

Authors:  P Niebes; G Ponard
Journal:  Biochem Pharmacol       Date:  1975-04-15       Impact factor: 5.858

2.  Technical study of the leucocyte migration inhibition test in agarose. Application to PPD and to hepatitis B antigen.

Authors:  P Erard
Journal:  Clin Exp Immunol       Date:  1974-11       Impact factor: 4.330

3.  The effect of (+)-catechin on the hepatic level of ATP and the lipid content of liver during experimental steatosis.

Authors:  A Gajdos; M Gajdos-Tërök; R Horn
Journal:  Biochem Pharmacol       Date:  1972-02-15       Impact factor: 5.858

4.  Cell-mediated immunity to hepatitis-associated antigen (HAA) demonstrated by leucocyte migration test during and after acute B hepatitis.

Authors:  P C Frei; P Erard; R Zinkernagel
Journal:  Biomedicine       Date:  1973-09-20

5.  Lymphocyte transformation and leucocyte migration-inhibition by Australia antigen.

Authors:  A A Laiwah; A K Chaudhuri; J R Anderson
Journal:  Clin Exp Immunol       Date:  1973-09       Impact factor: 4.330

6.  Tuberculin-induced migration inhibition of human peripheral leucocytes in agarose medium.

Authors:  J E Clausen
Journal:  Acta Allergol       Date:  1971-02

7.  Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis.

Authors:  A M Cochrane; A Moussouros; A D Thomsom; A L Eddleston; R Wiiliams
Journal:  Lancet       Date:  1976-02-28       Impact factor: 79.321

8.  Cell-mediated immune reactivity to hepatitis B surface antigen in liver diseases.

Authors:  M C de Moura; S J Vernace; F Paronetto
Journal:  Gastroenterology       Date:  1975-08       Impact factor: 22.682

9.  Immune response to hepatitis B surface antigen.

Authors:  A B Ibrahim; G N Vyas; H A Perkins
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

10.  Cell-mediated immunity in patients positive for hepatitis-associated antigen.

Authors:  F J Dudley; V Giustino; S Sherlock
Journal:  Br Med J       Date:  1972-12-30
View more
  3 in total

1.  Immune response to purified non-A, non-B hepatitis-related antigen demonstrated by leukocyte migration inhibition in patients recovering from the infection.

Authors:  A Nicole; O Spertini; D Lavanchy; P C Frei
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

2.  Treatment of chronic hepatitis B with recombinant leukocyte interferon and cyanidanol.

Authors:  K Kanai; S Morioka; T Nakajima; H Ishii; K Tamakoshi; H Matsuda; M Matsumoto; N Mizushima; Y Takehira
Journal:  Gastroenterol Jpn       Date:  1988-02

3.  Activation of suppressor function of human peripheral blood T cells by (+)cyanidanol-3: its application to chronic active liver diseases.

Authors:  S Kakumu; H Murakami; J Kuriki
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.